Common Contracts

2 similar Underwriting Agreement contracts by Check-Cap LTD, Edesa Biotech, Inc.

Check-Cap Ltd. 1,538,462 Ordinary Shares Underwriting Agreement
Underwriting Agreement • August 28th, 2026 • Check-Cap LTD • X-ray apparatus & tubes & related irradiation apparatus • New York

The Company has entered into that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of September 12, 2025, by and among MBody AI Corp, a Nevada Corporation (“MBody AI”), CC Merger Sub, Inc., a Nevada corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and the Company, pursuant to which Merger Sub will merge with and into MBody AI, with MBody AI surviving as a wholly-owned subsidiary of the Company.

3,870,500 Common Shares, Pre-Funded Warrants to Purchase up to 675,000 Common Shares, and Warrants to Purchase up to 4,545,500 Common Shares Underwriting Agreement
Underwriting Agreement • August 20th, 2026 • Edesa Biotech, Inc. • Pharmaceutical preparations • New York

Edesa Biotech, Inc., a company organized under the laws of British Columbia, Canada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule 1 (the “Underwriters”) an aggregate of (i) 3,870,500 common shares, without par value (“Common Shares”), of the Company (the “Underwritten Shares”), (ii) pre-funded warrants to purchase up to 675,000 Common Shares in the form set forth in Exhibit A hereto (the “Pre-Funded Warrants”), (iii) warrants to purchase up to 4,545,500 Common Shares (the “Underwritten Common Warrants”), and (iv) at the option of the Underwriters, up to 681,825 additional Common Shares (the “Option Shares” and, collectively with the Underwritten Shares, the “Shares”) with accompanying warrants to purchase up to 681,825 Common Shares (the “Option Common Warrants” and, together with the Underwritten Common Warrants, the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”). Each Share or Pre-Funded Warrant is being sold